Rilzabrutinib

Moderate

Rilzabrutinib Acetaminophen And Codeine Capital® & Codeine Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Clindamycin ANTIROBE Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Sertraline Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Buprenorphine Belbuca Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Colchicine Colcrys Explained Increased P-gp substrate with NTI exposure and an increased risk of P-gp substrate with NTI-related adverse reactions Details Rilzabrutinib Simvastatin Flolipid Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Abemaciclib Verzenio Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Acalabrutinib Calquence Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Alpelisib Piqray Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Apixaban Eliquis Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Aripiprazole Injection Abilify Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Asciminib Scemblix Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Atogepant Qulipta Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Avapritinib Ayvakit Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Avatrombopag Doptelet Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Belumosudil Rezurock Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Atorvastatin Atorvaliq Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Cariprazine Vraylar Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Abiraterone Abirtega Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Alfuzosin UroXatral Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Amlodipine Amvaz® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Avanafil Stendra Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Axitinib Inlyta Increased axitinib exposure and an increased risk of axitinib-related adverse reactions Details Rilzabrutinib Bedaquiline Sirturo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Bosutinib Bosulif Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Brexpiprazole Rexulti Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Brigatinib Alunbrig Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Budesonide Entocort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Budesonide Nasal Spray Rhinocort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Budesonide Oral Inhalation Pulmicort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Cabozantinib Cabometyx Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Cabozantinib (Thyroid Cancer) Cabometyx Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Capmatinib Tabrecta Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Clindamycin Injection ANTIROBE Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Clindamycin Topical C/T/S® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Clindamycin Vaginal Cleocin Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Cobimetinib Cotellic Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Cyclosporine Injection Atopica Increased P-gp substrate with NTI exposure and an increased risk of P-gp substrate with NTI-related adverse reactions Details Rilzabrutinib Cyclosporine Ophthalmic Cequa Increased P-gp substrate with NTI exposure and an increased risk of P-gp substrate with NTI-related adverse reactions Details Rilzabrutinib Darolutamide Nubeqa Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details